Typical timeline
4–12 months
Devices with prior CE or FDA approval typically move faster than novel, first-in-world submissions.
Saudi Arabia
SFDA Medical Device Marketing Authorization
Saudi Arabia's medical device authorization system, which relies substantially on prior CE or FDA approval.
Overview
What SFDA MDMA is and why it matters
The Saudi Food and Drug Authority (SFDA) regulates medical devices through the Medical Devices National Registry (MDNR) and a Marketing Authorization (MDMA) process. SFDA operates a reliance-based model, meaning devices already approved by a recognized reference regulator (such as the EU or FDA) generally face a more streamlined review than a first-in-world submission.
Requirements
What you'll need
The documentation and evidence a complete submission is normally built from.
- Medical Device National Registry (MDNR) establishment registration
- Marketing Authorization (MDMA) submission
- Reference approval (CE or FDA) streamlines review under SFDA's reliance model
- Authorized Representative based in Saudi Arabia
- GHTF/IMDRF-aligned technical file
Planning ranges
Typical timeline and estimated cost
Ranges illustrate general market patterns for this pathway — they are not a quote for a specific product.
Estimated cost
$8k–$50k
Lower than a from-scratch regulatory pathway given SFDA's reliance on recognized reference approvals.
Timelines and costs above are typical ranges illustrating general market patterns, not a quote or regulatory conclusion for your specific product. Actual figures depend on device classification, target country, and applicant readiness — professional review is required before relying on this for a business decision.
Where this applies
Applicable countries
Jurisdictions that recognise this certification. Scope and conditions still vary by product classification.
Saudi Arabia
Related
Regulatory Pathways
FAQ
Frequently asked questions
Do I need to run a Saudi clinical trial?
Generally not, if the device already holds a recognized reference approval (CE, FDA) — SFDA's reliance model is designed to avoid duplicating clinical evidence already reviewed elsewhere.
Reviewed packages
Buy a defined outcome
Pay for a market-access outcome — not a feature tour
Market Entry Sprint from $2,500 · Strategy Session $500 · Pathway Brief $1,800. Professional review required before business use. No patient data on public forms.
Reviewed launch planning
Need a SFDA MDMA pathway brief?
SFDA MDMA pathway briefs start at $1,800. Or book a $2,500 Market Entry Sprint that includes regulatory pathway outline, evidence flags, and a review call.
Professional review is required before business use.